This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Quiroga, T. Articles by Mezzano, D. Search for Related Content PubMed PubMed Citation Articles by Quiroga, T. Articles by Mezzano, D.

High prevalence of bleeders of unknown cause among patients with inherited mucocutaneous bleeding. A prospective study of 280 patients and 299 controls

Departments of Clinical Laboratory (TQ, MG); Hematology-Oncology (OP, EA, CM, SB, BM, PZ, JP, DM) School of Medicine, Pontificia Universidad Católica de Chile

Correspondence: Diego Mezzano, M.D., Department of Hematology-Oncology, School of Medicine, P. Universidad Católica de Chile, P.O. Box 114-D, Santiago, Chile E-mail: dmezzano{at}med.puc.cl

Background and Objectives: Mucocutaneous bleeding (MCB) is the main expression of inherited disorders of primary hemostasis. However, the relative prevalence of these disorders, their clinical differential diagnosis, and the proportion of patients with MCB of unknown cause (BUC) after an initial comprehensive laboratory testing are unknown.

Design and Methods: We studied prospectively 280 consecutive patients with MCB and 299 matched controls, using strict inclusion and exclusion criteria. A single physician recorded the clinical data in a bleeding score and estimated the severity of bleeding in clinical categories. Laboratory criteria for the diagnosis of von Willebrand’s disease (VWD) and platelet function defects were established from reference values derived from controls.

Results: Fifty patients (17.9%) had VWD (type 1VWD=45, type 2=5). Platelet function defects and mild clotting factor deficiencies were found in 65 (23.2%) and 11 (3.9%) patients, respectively. Thirteen (11.5%) patients had combined defects. The remaining 167(59.6%) patients had BUC, with prolonged bleeding time in 18.6% as their only abnormality. All these disorders, including BUC, were clinically undistinguishable. Moreover, no relationship was found between the severity of bleeding and VWF/platelet function variables.

Interpretation and Conclusions: The diagnostic efficacy of a first laboratory testing in patients with hereditary MCB is 40.4%. Most patients have a disease(s) of high prevalence but unknown pathogenesis. Concurrent bleeding disorders in the same patient are frequent. Our results support the proposal that low plasma VWF levels, but also platelet function defects, should be considered risk factors rather than unequivocal causes of hemorrhages.

Key words: bleeding of unknown cause, diagnosis of inherited disorders of primary hemostasis, mucous and skin bleeding, mild bleeding disorders, platelet function study, relative frequency of disorders of primary hemostasis.

This article has been cited by other articles:

				A. D. Mumford, B. B. Dawood, M. E. Daly, S. L. Murden, M. D. Williams, M. B. Protty, J. C. Spalton, M. Wheatley, S. J. Mundell, and S. P. Watson A novel thromboxane A2 receptor D304N variant that abrogates ligand binding in a patient with a bleeding diathesis Blood, January 14, 2010; 115(2): 363 - 369. [Abstract] [Full Text] [PDF]

				V. Serebruany, S. V. Rao, M. A. Silva, J. L. Donovan, A. O. Kannan, L. Makarov, S. Goto, and D. Atar Correlation of inhibition of platelet aggregation after clopidogrel with post discharge bleeding events: assessment by different bleeding classifications Eur. Heart J., January 2, 2010; 31(2): 227 - 235. [Abstract] [Full Text] [PDF]

				F. Rodeghiero, G. Castaman, and A. Tosetto How I treat von Willebrand disease Blood, August 6, 2009; 114(6): 1158 - 1165. [Abstract] [Full Text] [PDF]

				A. Minano, A. Ordonez, F. Espana, J. R. Gonzalez-Porras, R. Lecumberri, J. Fontcuberta, P. Llamas, F. Marin, A. Estelles, I. Alberca, et al. AB0 blood group and risk of venous or arterial thrombosis in carriers of factor V Leiden or prothrombin G20210A polymorphisms Haematologica, May 1, 2008; 93(5): 729 - 734. [Abstract] [Full Text] [PDF]